All In Biotech

Drug Trial Radar · NCT06804590

A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis

A Randomized, Double-blind, Parallel-group, Phase III Study to Compare the Clinical Efficacy, Safety, and Immunogenicity of Denosumab Injection 9MW0311 With Prolia® in Postmenopausal Women With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

280

Actual

Start

Nov 16, 2024

Primary completion

Apr 24, 2026

Study completion Jun 30, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia® in Chinese postmenopausal women with osteoporosis at high risk for fracture.

Conditions

  • Postmenopausal Women Osteoporosis

Interventions

  • 9MW0311Drug

    9MW0311 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

  • Prolia®Drug

    Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in lumbar spine(LS)-BMD at Week 53 (Month 12)Time frame: Baseline and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mabwell (Shanghai) Bioscience Co., Ltd.

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.